Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis - The Wegener's clinical occurrence of thrombosis (WeCLOT) study

Peter A. Merkel, Grace H. Lo, Janet T. Holbrook, Andrea K. Tibbs, Nancy B. Allen, John C. Davis, Gary S. Hoffman, Joseph McCune, E. William St. Clair, Ulrich Specks, Robert Spiera, Michelle Petri, John H. Stone

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Background: Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of VTEs in patients with Wegener granulomatosis. Design: Prospective, observational cohort study. Setting: A multicenter, randomized, double-blind, placebo-controlled treatment trial for Wegener granulomatosis. Patients: 180 patients with Wegener granulomatosis enrolled during periods of active disease. Measurements: Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates were calculated on the basis of time to first VTE. Results: Thirteen patients had VTEs before enrollment. During 228 person-years of prospective follow-up, 16 VTEs occurred in 167 patients with no history of VTE. Median time from enrollment to VTE for patients with an event was 2.1 months. The incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% CI, 4.0 to 11.4). Limitations: Although prospectively recorded, screening for VTEs did not occur. Conclusions: The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rates in the general population, patients with lupus, and patients with rheumatoid arthritis. These results have important implications for clinical care of patients with Wegener granulomatosis.

Original languageEnglish (US)
Pages (from-to)620-626
Number of pages7
JournalAnnals of Internal Medicine
Volume142
Issue number8
StatePublished - Apr 19 2005

Fingerprint

Granulomatosis with Polyangiitis
Thrombosis
Communication
Incidence
Embolism
Venous Thrombosis
Observational Studies
Rheumatoid Arthritis
Patient Care
Cohort Studies
Placebos
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brief communication : High incidence of venous thrombotic events among patients with Wegener granulomatosis - The Wegener's clinical occurrence of thrombosis (WeCLOT) study. / Merkel, Peter A.; Lo, Grace H.; Holbrook, Janet T.; Tibbs, Andrea K.; Allen, Nancy B.; Davis, John C.; Hoffman, Gary S.; McCune, Joseph; St. Clair, E. William; Specks, Ulrich; Spiera, Robert; Petri, Michelle; Stone, John H.

In: Annals of Internal Medicine, Vol. 142, No. 8, 19.04.2005, p. 620-626.

Research output: Contribution to journalArticle

Merkel, PA, Lo, GH, Holbrook, JT, Tibbs, AK, Allen, NB, Davis, JC, Hoffman, GS, McCune, J, St. Clair, EW, Specks, U, Spiera, R, Petri, M & Stone, JH 2005, 'Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis - The Wegener's clinical occurrence of thrombosis (WeCLOT) study', Annals of Internal Medicine, vol. 142, no. 8, pp. 620-626.
Merkel, Peter A. ; Lo, Grace H. ; Holbrook, Janet T. ; Tibbs, Andrea K. ; Allen, Nancy B. ; Davis, John C. ; Hoffman, Gary S. ; McCune, Joseph ; St. Clair, E. William ; Specks, Ulrich ; Spiera, Robert ; Petri, Michelle ; Stone, John H. / Brief communication : High incidence of venous thrombotic events among patients with Wegener granulomatosis - The Wegener's clinical occurrence of thrombosis (WeCLOT) study. In: Annals of Internal Medicine. 2005 ; Vol. 142, No. 8. pp. 620-626.
@article{d8ea1236130a4365839f3cacbb9821e5,
title = "Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis - The Wegener's clinical occurrence of thrombosis (WeCLOT) study",
abstract = "Background: Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of VTEs in patients with Wegener granulomatosis. Design: Prospective, observational cohort study. Setting: A multicenter, randomized, double-blind, placebo-controlled treatment trial for Wegener granulomatosis. Patients: 180 patients with Wegener granulomatosis enrolled during periods of active disease. Measurements: Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates were calculated on the basis of time to first VTE. Results: Thirteen patients had VTEs before enrollment. During 228 person-years of prospective follow-up, 16 VTEs occurred in 167 patients with no history of VTE. Median time from enrollment to VTE for patients with an event was 2.1 months. The incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95{\%} CI, 4.0 to 11.4). Limitations: Although prospectively recorded, screening for VTEs did not occur. Conclusions: The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rates in the general population, patients with lupus, and patients with rheumatoid arthritis. These results have important implications for clinical care of patients with Wegener granulomatosis.",
author = "Merkel, {Peter A.} and Lo, {Grace H.} and Holbrook, {Janet T.} and Tibbs, {Andrea K.} and Allen, {Nancy B.} and Davis, {John C.} and Hoffman, {Gary S.} and Joseph McCune and {St. Clair}, {E. William} and Ulrich Specks and Robert Spiera and Michelle Petri and Stone, {John H.}",
year = "2005",
month = "4",
day = "19",
language = "English (US)",
volume = "142",
pages = "620--626",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - Brief communication

T2 - High incidence of venous thrombotic events among patients with Wegener granulomatosis - The Wegener's clinical occurrence of thrombosis (WeCLOT) study

AU - Merkel, Peter A.

AU - Lo, Grace H.

AU - Holbrook, Janet T.

AU - Tibbs, Andrea K.

AU - Allen, Nancy B.

AU - Davis, John C.

AU - Hoffman, Gary S.

AU - McCune, Joseph

AU - St. Clair, E. William

AU - Specks, Ulrich

AU - Spiera, Robert

AU - Petri, Michelle

AU - Stone, John H.

PY - 2005/4/19

Y1 - 2005/4/19

N2 - Background: Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of VTEs in patients with Wegener granulomatosis. Design: Prospective, observational cohort study. Setting: A multicenter, randomized, double-blind, placebo-controlled treatment trial for Wegener granulomatosis. Patients: 180 patients with Wegener granulomatosis enrolled during periods of active disease. Measurements: Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates were calculated on the basis of time to first VTE. Results: Thirteen patients had VTEs before enrollment. During 228 person-years of prospective follow-up, 16 VTEs occurred in 167 patients with no history of VTE. Median time from enrollment to VTE for patients with an event was 2.1 months. The incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% CI, 4.0 to 11.4). Limitations: Although prospectively recorded, screening for VTEs did not occur. Conclusions: The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rates in the general population, patients with lupus, and patients with rheumatoid arthritis. These results have important implications for clinical care of patients with Wegener granulomatosis.

AB - Background: Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of VTEs in patients with Wegener granulomatosis. Design: Prospective, observational cohort study. Setting: A multicenter, randomized, double-blind, placebo-controlled treatment trial for Wegener granulomatosis. Patients: 180 patients with Wegener granulomatosis enrolled during periods of active disease. Measurements: Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates were calculated on the basis of time to first VTE. Results: Thirteen patients had VTEs before enrollment. During 228 person-years of prospective follow-up, 16 VTEs occurred in 167 patients with no history of VTE. Median time from enrollment to VTE for patients with an event was 2.1 months. The incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% CI, 4.0 to 11.4). Limitations: Although prospectively recorded, screening for VTEs did not occur. Conclusions: The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rates in the general population, patients with lupus, and patients with rheumatoid arthritis. These results have important implications for clinical care of patients with Wegener granulomatosis.

UR - http://www.scopus.com/inward/record.url?scp=20244380320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244380320&partnerID=8YFLogxK

M3 - Article

C2 - 15838068

AN - SCOPUS:20244380320

VL - 142

SP - 620

EP - 626

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -